Catherine Moukheibir Purchases Shares of MoonLake Immunotherapeutics
Catherine Moukheibir acquired 22,195 shares of MoonLake Immunotherapeutics.
Key Points
- Catherine Moukheibir bought 22,195 shares of MoonLake Immunotherapeutics on June 17, 2026.
- Shares of MoonLake Immunotherapeutics traded at $19.19, with a market cap of about $1.41 billion.
- MoonLake focuses on inflammatory disease therapies and is headquartered in Zug, Switzerland.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Catherine Moukheibir recently bought 22,195 shares of MoonLake Immunotherapeutics, trading on the NasdaqCM under the ticker MLTX. This transaction took place on June 17, 2026, and reflects a significant insider move within the company.
MoonLake Immunotherapeutics Stock Up 49.3%
Shares of NasdaqCM:MLTX were trading around $19.19. MoonLake Immunotherapeutics has a market cap of approximately $1.41 billion. Despite not being profitable, as indicated by its negative forward P/E ratio, the company has a beta of 1.036, suggesting moderate volatility. The stock's 52-week range spans from a low of $5.95 to a high of $62.75, with a 50-day moving average of $17.88 and a 200-day moving average of $19.01. The company maintains a strong liquidity position with a current ratio of 8.601 and a quick ratio of 7.887, though it has a debt-to-equity ratio of 39.682.
$MLTX stock price
Daily closing prices, year to date. Not investment advice.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a biotechnology company focused on developing treatments for inflammatory skin and joint diseases. The company is working on Sonelokimab, a novel treatment targeting conditions like hidradenitis suppurativa and psoriatic arthritis. Founded in 2021, MoonLake is based in Zug, Switzerland, and is led by CEO Dr. Jorge Santos da Silva. With around 130 employees, the company aims to advance therapies in dermatology and rheumatology.
Bottom Line
Catherine Moukheibir's recent purchase of MoonLake Immunotherapeutics shares highlights insider confidence in the company's potential. As a clinical-stage biotech firm, MoonLake is focused on innovative treatments for inflammatory diseases. Investors often watch insider transactions like this for insights into company sentiment, though it's important to remember that such moves are not always indicative of future performance.
Get MoonLake Immunotherapeutics alerts
New 13F filings, insider trades, and analyst moves on $MLTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.